Enovis (NYSE:ENOV) Stock Price Target Lowered at Canaccord Genuity Group

Enovis (NYSE:ENOV) had its price target reduced by Canaccord Genuity Group from $45.00 to $42.00 in a research report report published on Friday,Benzinga reports. They currently have a buy rating on the stock.

ENOV has been the topic of a number of other research reports. BTIG Research boosted their price objective on shares of Enovis from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Needham & Company LLC raised their target price on shares of Enovis from $34.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday. Citigroup reissued a “market outperform” rating on shares of Enovis in a research note on Wednesday, September 2nd. Finally, Wells Fargo & Company raised their price objective on shares of Enovis from $33.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.62.

Enovis Stock Down 5.1%

Enovis stock traded down $1.46 during trading on Friday, reaching $27.16. The stock had a trading volume of 2,304,734 shares, compared to its average volume of 1,449,886. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. The business has a 50 day moving average price of $19.91 and a 200 day moving average price of $23.09. The stock has a market cap of $1.57 billion, a PE ratio of -2.95 and a beta of 1.31. Enovis has a 52-week low of $16.70 and a 52-week high of $32.41.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.11. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The business had revenue of $558.73 million for the quarter, compared to analyst estimates of $557.12 million. During the same period last year, the firm posted $0.75 earnings per share. The company’s revenue for the quarter was up 1.8% compared to the same quarter last year. On average, analysts predict that Enovis will post 3.15 EPS for the current year.

Insiders Place Their Bets

In other news, insider Oliver Engert purchased 5,140 shares of the firm’s stock in a transaction on Thursday, September 3rd. The stock was bought at an average cost of $19.46 per share, for a total transaction of $100,024.40. Following the completion of the acquisition, the insider directly owned 61,238 shares of the company’s stock, valued at approximately $1,191,691.48. The trade was a 9.16% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Damien Mcdonald purchased 13,035 shares of the stock in a transaction dated Friday, September 4th. The stock was acquired at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the transaction, the chief executive officer owned 247,077 shares of the company’s stock, valued at $4,731,524.55. The trade was a 5.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have acquired 23,293 shares of company stock valued at $449,599. Company insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Enovis

Hedge funds have recently modified their holdings of the business. IFP Advisors Inc increased its position in Enovis by 5,590.5% during the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after acquiring an additional 1,174 shares during the period. Allworth Financial LP bought a new stake in Enovis in the 2nd quarter valued at $36,000. Integrated Wealth Concepts LLC acquired a new stake in Enovis in the 2nd quarter worth $39,000. Public Employees Retirement System of Ohio acquired a new stake in Enovis in the 2nd quarter worth $48,000. Finally, SBI Securities Co. Ltd. bought a new position in shares of Enovis during the 3rd quarter worth about $55,000. 98.45% of the stock is owned by institutional investors.

More Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q3 adjusted earnings were $0.88 per share, beating estimates of about $0.77 and topping $0.75 a year earlier. Revenue of $558.7 million slightly exceeded forecasts and grew 1.8% year over year. Enovis Q3 2026 results
• Positive Sentiment: Enovis raised its 2026 EPS guidance to $3.58–$3.79, signaling improved earnings expectations. Guidance and repurchase announcement
• Positive Sentiment: The company authorized a $200 million share-repurchase program, which could support per-share results and signal confidence in its prospects. Share-buyback announcement
• Positive Sentiment: Wells Fargo raised its target to $37 and maintained an Overweight rating; Needham lifted its target to $38 and BTIG to $42, both with Buy ratings. Wells Fargo analyst rating
• Neutral Sentiment: Canaccord lowered its price target from $45 to $42 but kept a Buy rating. Reports also highlighted product innovation and market-share gains, though market volatility remains a factor. Product innovation and share gains

Enovis Company Profile

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.